What Isomorphic Labs does
Isomorphic Labs is an Alphabet (Google) subsidiary building an “AI-first” drug design and digital biology platform aimed at accelerating how therapeutics are discovered and developed. The company was introduced in 2021 as an Alphabet “bet” launched from Google DeepMind, leveraging DeepMind’s AlphaFold progress while targeting broader drug-discovery workflows that go beyond protein structure prediction.
More
Isomorphic Labs’ productization focus is on deploying proprietary AI models as part of an end-to-end drug-design engine (including AlphaFold 3 in its workflow and a newer proprietary layer called the Isomorphic Labs Drug Design Engine, IsoDDE) to support both internal programs and multi-target research collaborations with pharmaceutical companies. Commercially, Isomorphic Labs’ strategy centers on (1) building a scalable AI drug-design engine, (2) translating model performance into decisions that drug discovery teams can use at speed (e.g., binding/pocket/affinity-style predictions and candidate prioritization), and (3) pairing that technology with partner biology and chemistry expertise via research collaborations. On the technology side, Isomorphic Labs positions IsoDDE as a bridge from structure prediction to real-world drug discovery requirements such as accuracy for protein–ligand interaction prediction and generalization to novel targets. As of 2026-08-31, Isomorphic Labs is in a scale-up phase: it announced a $2.1B Series B round in May 2026 (led by Thrive Capital) to “power” IsoDDE deployment and accelerate its pipeline toward the clinic, while also continuing to expand partnership and leadership initiatives (e.g., appointments and collaborations announced in 2025–2026).